On Tuesday, Skyworks Solutions Inc (NASDAQ:SWKS)’s shares inclined 0.80% to $103.97.
Skyworks Solutions Inc (SWKS) declared that its Board of Directors has declared a cash dividend of $0.26 per share of the Company’s common stock, representing a 100 percent enhance from the prior quarterly dividend of $0.13 per share. Based on the closing price of Skyworks’ stock on June 17, 2015, the raised dividend represents roughly a one percent yield, or $1.04 per share on an annualized basis. The dividend is payable on August 27, 2015, to stockholders of record as of the close of business on August 6, 2015.
Skyworks Solutions, Inc., together with its auxiliaries, designs, develops, manufactures, and markets analog and mixed signal semiconductors worldwide. Its product portfolio comprises amplifiers, attenuators, battery chargers, circulators, DC/DC converters, demodulators, detectors, diodes, directional couplers, filters, front-end modules, hybrids, infrastructure radio frequency subsystems, isolators, LED drivers, mixers, modulators, optocouplers, optoisolators, phase shifters, phase locked loops/synthesizers/VCOs, power dividers/combiners, power administration devices, receivers, switches, technical ceramics, and voltage regulators.
Hewlett-Packard Company (NYSE:HPQ)’s shares gained 0.67% to $30.66.
In conjunction with Helmerich & Payne, Inc.’s (HP) third quarter earnings release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, July 30, 2015, at 11:00 a.m. (ET) with John Lindsay, President and CEO, and Juan Pablo Tardio, Vice President and CFO.
Helmerich & Payne, Inc. primarily operates as a contract drilling company in South America, the Middle East, and Africa. It provides drilling rigs, equipment, personnel, and camps on a contract basis to explore for and develop oil and gas from onshore areas and fixed platforms, tension-leg platforms, and spars in offshore areas. As of November 13, 2014, the company’s fleet comprised of 333 land rigs in the U.S., 37 international land rigs, and 9 offshore platform rigs. Its contract drilling business operates through three reportable segments: U.S. Land, Offshore, and International Land.
At the end of Tuesday’s trade, Tile Shop Hldgs, Inc. (NASDAQ:TTS)‘s shares dipped -5.68% to $13.77
Tile Shop Holdings, Inc. (TTS) a specialty retailer of manufactured and natural stone tiles, setting and maintenance materials, and related accessories, recently declared results for its second quarter ended June 30, 2015.
Net sales grew 13.6% to $75.7 million for the quarter ended June 30, 2015 contrast with $66.7 million for the second quarter of 2014. The $9.0 million enhance in sales was due to incremental net sales of $5.3 million from stores not comprised of in the comparable store base, while comparable store sales raised 5.7% or $3.8 million in the quarter.
Gross margin was 67.8% for the quarter contrast with 69.8% for the second quarter of 2014. The decline in gross margin was primarily attributable to pricing tests conducted in certain markets during the quarter, higher mix of customer delivery sales and inventory transition activity. Administration anticipates that the lower gross margin rate will be largely isolated to the second quarter. Gross margin for the six months ended June 30, 2015 was 68.8%.
Tile Shop Holdings, Inc. operates as a specialty retailer of manufactured and natural stone tiles, setting and maintenance materials, and related accessories in the United States. It offers about 4,000 products, counting ceramic, porcelain, glass, and metal tiles; and marble, granite, quartz, sandstone, travertine, slate, and onyx tiles primarily under the Rush River and Fired Earth brand names.
Cleveland BioLabs, Inc. (NASDAQ:CBLI), ended its Tuesday’s trading session with 16.62% gain, and closed at $4.00.
Cleveland BioLabs, Inc. (CBLI) declared that on August 3, 2015, it will report its financial results for the second quarter and six-month period ended June 30, 2015, and will host a conference call at 10:00 a.m. ET.
Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate is Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is developing as a radiation countermeasure for prevention of death from acute radiation syndrome, and as an oncology drug.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
